Institute of Life Science 2 Internal Atrium

Dr Jezabel Garcia Parra

Aelod Cyswllt

Faculty of Medicine Health and Life Science

j.garciaparra@abertawe.ac.uk

Ar gael ar gyfer Goruchwyliaeth Ôl-raddedig

Trosolwg

Mae gwaith ymchwil Jezabel yn canolbwyntio ar ddatblygu therapiwteg uwch mewn meddygaeth drachywir ac astudio biofarcwyr canser newydd.
Ym Mhrifysgol Abertawe, mae wedi bod yn rhan uniongyrchol o brosiectau datblygu ADC, darganfod targedau ADC newydd, astudio ecsosomau ar gyfer rhaglenni therapiwtig, datblygu modelau meithriniadau 3D a gweithredu gweithdrefnau delweddu cynnwys uwch.
Mae ei diddordebau clinigol wedi canolbwyntio bob amser ar y maes oncoleg, yn bennaf archwilio canserau gynaecolegol (yr ofari, endometriaidd a cheg y groth) a chanser y fron.
Mae ei gyrfa wyddonol wedi ymwneud bob amser â meddygaeth trawsfudol a’i nod yw cyfrannu drwy ymchwil cyn-glinigol i ddatblygu triniaethau ac adnoddau canser newydd er mwyn gwneud diagnosis cynnar o ganser.

Meysydd Arbenigedd

• Canser
• Datblygu cyffuriau
• Darganfod biofarcwyr
• Bioleg Atgenhedlol
• Cyfieuau Cyffuriau Gwrthgyrff
• Ecosomau
• Ymchwil Biofeddygol Trawsfudol

Cyhoeddiadau

Uchafbwyntiau Ymchwil

García-Parra, J., Dalmases, A., Morancho, B., Arpí, O., Menendez, S., Sabbaghi, M., Zazo, S., Chamizo, C., Madoz, J., Eroles, P., Servitja, S., Tusquets, I., Yelamos, J., Lluch, A., Arribas, J., Rojo, F., Rovira, A., Albanell, J., & Garcia Parra, J. (2014). Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer. European Journal of Cancer, 50(15), 2725-2734.
https://doi.org/10.1016/j.ejca.2014.07.004, SU Repository: https://cronfa.swan.ac.uk/Record/cronfa38411
Rojo, F., García-Parra, J., Zazo, S., Tusquets, I., Ferrer-Lozano, J., Menendez, S., Eroles, P., Chamizo, C., Servitja, S., Ramírez-Merino, N., Lobo, F., Bellosillo, B., Corominas, J., Yelamos, J., Serrano, S., Lluch, A., Rovira, A., Albanell, J., & Garcia Parra, J. (2012). Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer. Annals of Oncology, 23(5), 1156-1164.
https://doi.org/10.1093/annonc/mdr361, SU Repository: https://cronfa.swan.ac.uk/Record/cronfa38412
Howard, D., Garcia-Parra, J., Healey, G., Amakiri, C., Margarit, L., Francis, L., Gonzalez, D., Conlan, R., Conlan, S., & Garcia Parra, J. (2016). Antibody–drug conjugates and other nanomedicines: the frontier of gynaecological cancer treatment. Interface Focus, 6(6), 20160054
https://doi.org/10.1098/rsfs.2016.0054, SU Repository: https://cronfa.swan.ac.uk/Record/cronfa33095
Healey, G., Pan Castillo, B., Garcia Parra, J., Davies, J., Roberts, S., Jones, E., Dhar, K., Nandanan, S., Tofazzal, N., Piggott, L., Clarkson, R., Seaton, G., Frostell, A., Fagge, T., McKee, C., Margarit, L., Conlan, S., & Gonzalez, D. (2019). Antibody drug conjugates against the receptor for advanced glycation end products (RAGE), a novel therapeutic target in endometrial cancer. Journal for ImmunoTherapy of Cancer, 7(1)
https://doi.org/10.1186/s40425-019-0765-z, SU Repository: https://cronfa.swan.ac.uk/Record/cronfa52619
Pisano, S., Wang, X., Garcia Parra, J., Gazze, S., Edwards, K., Feltracco, V., Hu, Y., He, L., Gonzalez, D., Francis, L., Conlan, S., & Li, C. (2020). Nanomicelles potentiate histone deacetylase inhibitor efficacy in vitro. Cancer Nanotechnology, 11(1)
https://doi.org/10.1186/s12645-020-00070-8, SU Repository: https://cronfa.swan.ac.uk/Record/cronfa55789
Howard, D., James, D., Murphy, K., Garcia Parra, J., Pan Castillo, B., Rex, S., Moul, A., Jones, E., Bilbao Asensio, M., Michue-Seijas, S., Lutchman-Singh, K., Margarit, L., Francis, L., Rees, P., Gonzalez, D., & Conlan, S. (2021). Dinaciclib, a Bimodal Agent Effective against Endometrial Cancer. Cancers, 13(5), 1135
https://doi.org/10.3390/cancers13051135, SU Repository: https://cronfa.swan.ac.uk/Record/cronfa56783
Howard, D., James, D., Garcia Parra, J., Pan Castillo, B., Worthington, J., Williams, N., Bentham, Z., Rees, S., Lutchman-Singh, K., Francis, L., Rees, P., Margarit, L., Conlan, S., & Gonzalez, D. (2022). Dinaciclib as an effective pan-cyclin dependent kinase inhibitor in platinum resistant ovarian cancer. Frontiers in Oncology, 12
https://doi.org/10.3389/fonc.2022.1014280, SU Repository: https://cronfa.swan.ac.uk/Record/cronfa61957
Williams, M., Howard, D., Donnelly, C., Izadi, F., Garcia Parra, J., Pugh, M., EDWARDS, K., Lutchman-Sigh, K., Jones, S., Margarit, L., Francis, L., Conlan, S., Taraballi, F., & Gonzalez, D. (2024). Adipocyte derived exosomes promote cell invasion and challenge paclitaxel efficacy in ovarian cancer. Cell Communication and Signaling, 22(1)
https://doi.org/10.1186/s12964-024-01806-4, SU Repository: https://cronfa.swan.ac.uk/Record/cronfa67596

Holl Ymchwil

Erthyglau Cylchgronau

Williams, M., Howard, D., Donnelly, C., Izadi, F., Garcia Parra, J., Pugh, M., EDWARDS, K., Lutchman-Sigh, K., Jones, S., Margarit, L., Francis, L., Conlan, S., Taraballi, F., & Gonzalez, D. (2024). Adipocyte derived exosomes promote cell invasion and challenge paclitaxel efficacy in ovarian cancer. Cell Communication and Signaling, 22(1)
https://doi.org/10.1186/s12964-024-01806-4, SU Repository: https://cronfa.swan.ac.uk/Record/cronfa67596
Howard, D., James, D., Garcia Parra, J., Pan Castillo, B., Worthington, J., Williams, N., Bentham, Z., Rees, S., Lutchman-Singh, K., Francis, L., Rees, P., Margarit, L., Conlan, S., & Gonzalez, D. (2022). Dinaciclib as an effective pan-cyclin dependent kinase inhibitor in platinum resistant ovarian cancer. Frontiers in Oncology, 12
https://doi.org/10.3389/fonc.2022.1014280, SU Repository: https://cronfa.swan.ac.uk/Record/cronfa61957
Howard, D., James, D., Murphy, K., Garcia Parra, J., Pan Castillo, B., Rex, S., Moul, A., Jones, E., Bilbao Asensio, M., Michue-Seijas, S., Lutchman-Singh, K., Margarit, L., Francis, L., Rees, P., Gonzalez, D., & Conlan, S. (2021). Dinaciclib, a Bimodal Agent Effective against Endometrial Cancer. Cancers, 13(5), 1135
https://doi.org/10.3390/cancers13051135, SU Repository: https://cronfa.swan.ac.uk/Record/cronfa56783
Pisano, S., Wang, X., Garcia Parra, J., Gazze, S., Edwards, K., Feltracco, V., Hu, Y., He, L., Gonzalez, D., Francis, L., Conlan, S., & Li, C. (2020). Nanomicelles potentiate histone deacetylase inhibitor efficacy in vitro. Cancer Nanotechnology, 11(1)
https://doi.org/10.1186/s12645-020-00070-8, SU Repository: https://cronfa.swan.ac.uk/Record/cronfa55789
Healey, G., Pan Castillo, B., Garcia Parra, J., Davies, J., Roberts, S., Jones, E., Dhar, K., Nandanan, S., Tofazzal, N., Piggott, L., Clarkson, R., Seaton, G., Frostell, A., Fagge, T., McKee, C., Margarit, L., Conlan, S., & Gonzalez, D. (2019). Antibody drug conjugates against the receptor for advanced glycation end products (RAGE), a novel therapeutic target in endometrial cancer. Journal for ImmunoTherapy of Cancer, 7(1)
https://doi.org/10.1186/s40425-019-0765-z, SU Repository: https://cronfa.swan.ac.uk/Record/cronfa52619
Howard, D., Garcia-Parra, J., Healey, G., Amakiri, C., Margarit, L., Francis, L., Gonzalez, D., Conlan, R., Conlan, S., & Garcia Parra, J. (2016). Antibody–drug conjugates and other nanomedicines: the frontier of gynaecological cancer treatment. Interface Focus, 6(6), 20160054
https://doi.org/10.1098/rsfs.2016.0054, SU Repository: https://cronfa.swan.ac.uk/Record/cronfa33095
García-Parra, J., Dalmases, A., Morancho, B., Arpí, O., Menendez, S., Sabbaghi, M., Zazo, S., Chamizo, C., Madoz, J., Eroles, P., Servitja, S., Tusquets, I., Yelamos, J., Lluch, A., Arribas, J., Rojo, F., Rovira, A., Albanell, J., & Garcia Parra, J. (2014). Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer. European Journal of Cancer, 50(15), 2725-2734.
https://doi.org/10.1016/j.ejca.2014.07.004, SU Repository: https://cronfa.swan.ac.uk/Record/cronfa38411
Rojo, F., García-Parra, J., Zazo, S., Tusquets, I., Ferrer-Lozano, J., Menendez, S., Eroles, P., Chamizo, C., Servitja, S., Ramírez-Merino, N., Lobo, F., Bellosillo, B., Corominas, J., Yelamos, J., Serrano, S., Lluch, A., Rovira, A., Albanell, J., & Garcia Parra, J. (2012). Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer. Annals of Oncology, 23(5), 1156-1164.
https://doi.org/10.1093/annonc/mdr361, SU Repository: https://cronfa.swan.ac.uk/Record/cronfa38412

Modiwlau a Addysgir

PMNM11 Nanomedicines, pharmaceuticals and advanced therapeutics

This module will explore the history and development of molecular medicines and pharmaceuticals, providing the basis for an advanced understanding of next generation therapeutic approaches. Using landmark technology and chemical development phases informed by separation science and mass spectrometry, the module uses an application driven approach to provide the student with an extensive knowledgebase of drug development, the pharmaceutical industry and nanotherapeutics. Students will be able to characterize and map the path of a drug from administration, to metabolism and elimination, and critically evaluate drug design and delivery approaches. Traditional small chemical entities used in molecular medicine will be outlined, using drugs such as taxols and tamoxifen as exemplars. Common target oncology and non-oncology disorders will provide the context; with students encouraged to explore targeted nanoparticle fabrication, drug encapsulation and release profiling, from early first generation drugs such as Abraxane to second generation biologically targeted SMART delivery systems. Future molecular medicines such as antibody drug conjugates and kinase inhibitors will be taught by guest lectures from industry and clinicians, covering the spectrum of drug development to delivery and clinical considerations.

Grantiau a Phrosiectau Allweddol

SMARTExpertise fund RISE: ReNeuron, IgInnovations and Swansea University development of Exosomes towards clinical utility 2018 - 2020
Cronfa Rhwydwaith Ymchwil Gwyddorau Bywyd Cymru ADC targets from in-silico high-throughput screening identification into target validation 2017 - 2018
Cronfa Bontio Gwyddorau Bywyd, Cronfa AgorIP SNIPER ADC development for gynaecological cancers 2014

Hanes Gyrfa

Cynorthwyydd Ymchwil a Myfyriwr Doethuriaeth , Barcelona Biomedical Research Park (PRBB) - Sbaen

2006 - Presennol
Swyddog Ymchwil , Grŵp Ymchwil Bioleg Atgenhedlol ac Oncoleg Gynaecolegol (RBGO), Ysgol Feddygaeth Prifysgol Abertawe

2014 - Presennol

Dr Jezabel Garcia Parra

Cyfeiriad ebost

Trosolwg

Meysydd Arbenigedd

Cyhoeddiadau

Uchafbwyntiau Ymchwil

Holl Ymchwil

Erthyglau Cylchgronau

Modiwlau a Addysgir

PMNM11 Nanomedicines, pharmaceuticals and advanced therapeutics

Grantiau a Phrosiectau Allweddol

SMARTExpertise fund RISE: ReNeuron, IgInnovations and Swansea University development of Exosomes towards clinical utility 2018 - 2020

Cronfa Rhwydwaith Ymchwil Gwyddorau Bywyd Cymru ADC targets from in-silico high-throughput screening identification into target validation 2017 - 2018

Cronfa Bontio Gwyddorau Bywyd, Cronfa AgorIP SNIPER ADC development for gynaecological cancers 2014

Hanes Gyrfa

Cynorthwyydd Ymchwil a Myfyriwr Doethuriaeth , Barcelona Biomedical Research Park (PRBB) - Sbaen

Swyddog Ymchwil , Grŵp Ymchwil Bioleg Atgenhedlol ac Oncoleg Gynaecolegol (RBGO), Ysgol Feddygaeth Prifysgol Abertawe